 Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 3 | 3 | 6 | | 2011 | 3 | 1 | 4 | | 2012 | 5 | 2 | 7 | | 2013 | 4 | 4 | 8 | | 2014 | 3 | 4 | 7 | | 2015 | 4 | 2 | 6 | | 2016 | 3 | 4 | 7 | | 2017 | 6 | 3 | 9 | | 2018 | 5 | 5 | 10 | | 2019 | 11 | 1 | 12 | | 2020 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
Whiteway SL, Betts AM, O'Neil ER, Green AL, Gilani A, Orr BA, Mathis DA. Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case. J Pediatr Hematol Oncol. 2020 11; 42(8):e813-e818.
-
Malik F, Wang L, Yu Z, Edelman MC, Miles L, Clay MR, Hedges D, Brennan RC, Nichols KE, Beth McCarville M, Bahrami A. Benign infiltrative myofibroblastic neoplasms of childhood with USP6 gene rearrangement. Histopathology. 2020 Nov; 77(5):760-768.
-
Sobral LM, Hicks HM, Parrish JK, McCann TS, Hsieh J, Goodspeed A, Costello JC, Black JC, Jedlicka P. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Mol Oncol. 2020 10; 14(10):2471-2486.
-
Zhang Y, Guo Y, Gough SM, Zhang J, Vann KR, Li K, Cai L, Shi X, Aplan PD, Wang GG, Kutateladze TG. Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion. Nat Commun. 2020 07 03; 11(1):3339.
-
O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA, Choi J, Bayliss R, Fry AM. EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. J Cell Sci. 2020 05 11; 133(9).
-
Liu H, Lee S, Zhang Q, Chen Z, Zhang G. The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments. Mol Carcinog. 2020 07; 59(7):839-851.
-
Doebele RC. Acquired Resistance Is Oncogene and Drug Agnostic. Cancer Cell. 2019 10 14; 36(4):347-349.
-
Lake JA, Donson AM, Prince E, Davies KD, Nellan A, Green AL, Mulcahy Levy J, Dorris K, Vibhakar R, Hankinson TC, Foreman NK, Ewalt MD, Kleinschmidt-DeMasters BK, Hoffman LM, Gilani A. Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. Pediatr Blood Cancer. 2020 01; 67(1):e28028.
-
Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes Dev. 2019 09 01; 33(17-18):1265-1279.
-
Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|